Valérie Boige, Hélène Blons, Eric François, Meher Ben Abdelghani, Jean-Marc Phelip, Valerie Le Brun-Ly, Laurent Mineur, Marie Pierre Galais, Anne-Laure Villing, Vincent Hautefeuille, Laurent Miglianico, Christelle De La Fouchardière, Dominique Genet, Nadia Levasseur, Charles-Briac Levaché, Nicolas Penel, Emmanuel Mitry, Stéphane Jacquot, Thomas Aparicio, Emilie Brument, Sophie Gourgou, Florence Castan, Olivier Bouché
IMPORTANCE: The optimal maintenance strategy after induction chemotherapy with anti-epidermal growth factor receptor antibody for patients with RAS wild-type metastatic colorectal cancer (mCRC) remains to be debated. OBJECTIVE: To evaluate the efficacy and safety of maintenance therapy with single-agent cetuximab after FOLFIRI (leucovorin [folinic acid], fluorouracil, and irinotecan) plus cetuximab induction therapy. DESIGN, SETTING, AND PARTICIPANTS: The TIME (Treatment After Irinotecan-Based Frontline Therapy: Maintenance With Erbitux]) (PRODIGE 28 [Partenariat de Recherche en Oncologie Digestive]-UCGI 27 [UniCancer GastroIntestinal Group]) phase 2 noncomparative, multicenter randomized clinical trial was conducted from January 15, 2014, to November 23, 2018, among 139 patients with unresectable RAS wild-type mCRC...
September 5, 2023: JAMA Network Open